Lenvatinib: New Kid On The Block

Lenvatinib: New Kid on the Block

Lenvatinib increases progression free survival with everolimus in metastatic renal cell carcinoma

Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC

Lenvatinib Breakthrough Designation, New Drug Applications for NSCLC and STS, and More

Lenvatinib in Renal Cell Carcinoma

Lenvatinib Perspective program

Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC

Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer

Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC

New Drug Meets Endpoint

Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

Dr. Cohen on Lenvatinib in First- or Second-Line Thyroid Cancer

New Kids on the block (Full besetning og aspirantsolo)

Norges musikkorps forbund - Topic

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

Lenvatinib As Up-front Therapy for Unresectable HCC

Homicide: Hours to Kill

Crime+Investigation Play • S4 E9 • New Kid on the Block

Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC

Targeted Oncology

Practical Experience With Lenvatinib/Everolimus in RCC